Observational Study of Adult Participants With Diabetic Macular Edema and Suboptimal Response to Anti-Vascular Endothelial Growth Factor Treated With Dexamethasone Intravitreal Implant

Inclusion Criteria: * Participant diagnosed with DME in the study eye * Study eye has received at least 3 and no more than 9 anti-VEGF injections in the 12 months prior to DEX-I initiation * Study eye newly prescribed DEX-I. The prescribing decision lies with the physician and reflects their standard practice * Participant showing a suboptimal response to anti-VEGF at Baseline in the study eye Exclusion Criteria: * Any concomitant ocular or neurologic condition in the study eye that could cause macular edema or affect vision (except cataract) * History of ocular surgery within 60 days of Baseline in the study eye * History of Pan-Retinal Photocoagulation (PRP) or sectorial photocoagulation in the study eye in the 3 months prior to Baseline * Significant media opacities in the study eye limiting Optical Coherence Tomography (OCT) quality * Uncontrolled Ocular Hypertension (OHT) or advanced glaucoma in the study eye * Active ocular inflammation in either eye * Study eyes that are aphakic with Posterior Capsule Rent (PCR), Anterior Chamber Intraocular Lens (ACIOL), iris or scleral-fixed Intraocular Lens (IOL) or history of complicated cataract surgery with PCR * Prior use of intravitreal corticosteroids in the study eye * Patients with contraindications to DEX-I